GSK Pharma Q4 results: Net profit rises 46% to ₹193 crore, dividend announced

Revenue from operations for the quarter under review stood at ₹910.8 crore, compared to ₹782.1 crore in Q4 FY23, reflecting a 16% growth.

Total expenses in the fourth quarter were higher at ₹691.4 crore against ₹635.5 crore in the same period a year ago.

Dividend announced

The company's board also recommended a dividend of ₹32 per share on face value of ₹10 each for the year ended March 31, 2024, subject to approval of shareholders.

For FY24, the pharma major's revenue grew 6% to ₹3,407 crore, while the net profit fell 3.8% to ₹584.6 crore.

Bhushan Akshikar, Managing Director of GSK, said, "For Q4, we delivered a strong double-digit growth and a robust performance across our general medicines, speciality and vaccines portfolio. Our general medicines portfolio recorded strong double-digit growth of 12% for the quarter, driven by key focus brands Augmentin, Ceftum and Calpol. Despite the NLEM impact in previous quarters, all promoted brands outpaced their respective categories in growth and gained market share".

He said the company has seen a steady uptick in adult and paediatric segments. "This business delivered a Q4 growth of 35%," Akshikar added.

Meanwhile, shares of GSK closed 13.7% higher at ₹2,299 on the NSE. Intraday, the stock hit a high of ₹2,343.2.

It was trading 13.2% higher at ₹2,291 on the BSE.

The company's market capitalisation (m-cap) stands at ₹38,954 crore, while the free float m-cap is ₹9,349 crore.